Inimex Pharmaceuticals
Founded Year
2001Stage
Series B | AliveTotal Raised
$25.5MLast Raised
$22M | 15 yrs agoAbout Inimex Pharmaceuticals
Inimex Pharmaceuticals, Inc. is focused on the development and commercialization of Innate Defense Regulators (IDRs), first in class drugs that selectively trigger the body's innate defenses without causing inflammation. IDR products have major market potential for infectious disease, cancer, and inflammatory disease. These products will reduce morbidity and mortality in the rapidly growing population of immune suppressed and elderly patients who are "at-risk" for these disorders. IDR products will also benefit healthcare payors by reducing costs associated with hospitalization. Inimex' lead IDR product IMX942 targets a broad spectrum of life-threatening hospital infections, many of which are caused by antibiotic-resistant bacteria such as methicillin-resistant Staphylococcus aureus (MRSA) or vancomycin-resistant Enterococcus (VRE). IMX942 is active against both normal and drug-resistant bacteria and its ability to stimulate host innate immune defenses is not susceptible to bacterial antibiotic resistance mechanisms. The first clinical indication for IMX942 will be the prevention of infections associated with cancer chemotherapy-induced immune suppression. nnAdditional IDR product candidates will be developed for distinct disease areas, with an emphasis on inflammatory disease and demonstration of the potential for orally available IDR dosage forms.
Missing: Inimex Pharmaceuticals's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Inimex Pharmaceuticals's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Inimex Pharmaceuticals
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Inimex Pharmaceuticals is included in 1 Expert Collection, including Biopharma Tech.
Biopharma Tech
5,241 items
Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.
Inimex Pharmaceuticals Patents
Inimex Pharmaceuticals has filed 1 patent.
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
10/4/2006 | 2/28/2012 | Clusters of differentiation, Transcription factors, Immune system, Protein domains, Protein families | Grant |
Application Date | 10/4/2006 |
|---|---|
Grant Date | 2/28/2012 |
Title | |
Related Topics | Clusters of differentiation, Transcription factors, Immune system, Protein domains, Protein families |
Status | Grant |
Inimex Pharmaceuticals Frequently Asked Questions (FAQ)
When was Inimex Pharmaceuticals founded?
Inimex Pharmaceuticals was founded in 2001.
Where is Inimex Pharmaceuticals's headquarters?
Inimex Pharmaceuticals's headquarters is located at 3650 Wesbrook Mall, Vancouver.
What is Inimex Pharmaceuticals's latest funding round?
Inimex Pharmaceuticals's latest funding round is Series B.
How much did Inimex Pharmaceuticals raise?
Inimex Pharmaceuticals raised a total of $25.5M.
Who are the investors of Inimex Pharmaceuticals?
Investors of Inimex Pharmaceuticals include GrowthWorks, BDC Venture Capital, Canadian Medical Discoveries Fund, Discovery Capital, BC Advantage Funds and 9 more.
Who are Inimex Pharmaceuticals's competitors?
Competitors of Inimex Pharmaceuticals include Humanetics, Inhibikase Therapeutics, Aquinox Pharmaceuticals, Tetraphase Pharmaceuticals, Bexion Pharmaceuticals, CoImmune, Midway Biome, PrevaCept Infection Control, Acetylon Pharmaceuticals, Nabriva Therapeutics and 26 more.
Compare Inimex Pharmaceuticals to Competitors
Catena Pharmaceuticals is focused on the development and commercialization of GPCR antagonists, particularly in the areas of cancer and fibrotic disease. Catena's chemistry is capable of affecting a specific class of GPCRs known to be relevant in a variety of disease states.
Bexion Pharmaceuticals is a company focused on the development of cures for cancer. Specifically, the company is interested in first entering the clinic with a glioma cancer indication, possibly simultaneously with a leukemia or pancreatic cancer indication.
CoImmune, fka Argos Therapeutics, is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases. Using biological components from each patient, the company's immunotherapies employ the patient's dendritic cells to activate an immune response specific to the patient's disease.
ISA Pharmaceuticals develops treatments for various cancers and infectious diseases. It focuses on the development of synthetic peptide vaccines that boost the immune system to recognize specific peptides associated with specific types of cancer and subsequently destroy the tumor cells. The company was founded in 2004 and is based in Oestgeest, Netherlands.
Anza Therapeutics is developing active immunotherapies for the treatment of infectious diseases and cancer. Anza's therapeutic agents are based on its proprietary live-attenuated and Killed But Metabolically Active (KBMA) Listeria platforms which can be engineered to express antigens specific to the disease being treated.
IBI has recently demonstrated that treatment of Bacillus anthracis infected mice with a combination of the antibiotic ciprofloxacin and partially purified antibodies against anthrax protective antigen increased survival rates in comparison with antibiotic treatment alone.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.